Compare ZLAB & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZLAB | WGS |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.7B |
| IPO Year | 2017 | 2020 |
| Metric | ZLAB | WGS |
|---|---|---|
| Price | $26.25 | $83.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $49.60 | ★ $120.71 |
| AVG Volume (30 Days) | ★ 1.2M | 455.5K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 38.46 | ★ 62.37 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $460,156,000.00 | $427,539,000.00 |
| Revenue This Year | $9.75 | $29.98 |
| Revenue Next Year | $26.03 | $25.92 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 15.33 | ★ 39.97 |
| 52 Week Low | $15.96 | $32.21 |
| 52 Week High | $34.72 | $170.87 |
| Indicator | ZLAB | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 60.90 | 58.15 |
| Support Level | $16.98 | $81.37 |
| Resistance Level | $27.08 | $94.82 |
| Average True Range (ATR) | 0.84 | 3.95 |
| MACD | -0.19 | -0.65 |
| Stochastic Oscillator | 53.72 | 48.70 |
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.